SPIKE-CAP - Blocking SARS-CoV-2 Spike protein through Computer-Aided design of Peptide inhibitors

  • Funded by Partnership for Advanced Computng in Europe (PRACE)
  • Total publications:0 publications

Grant number: unknown

Grant search

Key facts

  • Disease

    COVID-19
  • Funder

    Partnership for Advanced Computng in Europe (PRACE)
  • Principal Investigator

    Alfonso Gautieri
  • Research Location

    Italy, United States of America
  • Lead Research Institution

    Politecnico di Milano
  • Research Priority Alignment

    N/A
  • Research Category

    Therapeutics research, development and implementation

  • Research Subcategory

    Pre-clinical studies

  • Special Interest Tags

    N/A

  • Study Type

    Non-Clinical

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Not Applicable

  • Vulnerable Population

    Not applicable

  • Occupations of Interest

    Not applicable

Abstract

SPIKE-CAP - Blocking SARS-CoV-2 Spike protein through Computer-Aided design of Peptide inhibitors is a PRACE-awarded project led by Dr Alfonso Gautieri from the Polytechnic University of Milan, Italy. The SPIKE-CAP project aims to design antiviral peptides (short chains of amino acids, linked by peptide bonds) with ultra-high affinity for the coronavirus spike protein (S) by using high-throughput computational deep scanning mutagenesis. The most promising candidate will be tested by a partner lab at Massachusetts Institute of Technology (MIT) with bio-layer interferometry (BLI) and X-ray crystallography. Using a computational scanning mutagenesis method, developed at the Polytechnic University of Milan and based on Simulated Annealing Molecular Dynamics, the team will computationally screen peptide mutations and rank them by binding affinity to S protein, while a machine learning algorithm, developed by MIT, will ensure the correct helical folding. The project has the potential to identify peptides with ultra-high affinity to the spike of the virus, which would outcompete binding with human ACE2, thereby preventing viral infection. The team expects that this project could be helpful for future design of peptidie therapeutics. To support this innovative approach, PRACE awarded the project with 44 000 000 core hours on Marconi100, hosted by CINECA, Italy.